Effects of β-glucan and Vitamin D Supplementation on Inflammatory Parameters in Patients with Diabetic Retinopathy.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in the context of diabetic retinopathy and glaucoma in this controlled clinical trial publication.

The objective of this article is to evaluate the potential effects of beta-glucan and vitamin D supplementation in patients with diabetic retinopathy.

Why It Was Studied

The researchers evaluated the levels of several parameters of inflammatory reactions (C-reactive protein [CRP], serum amyloid A [SAA], and interleukin- [IL-] 6), leptin, and vitamin D.

Using a 3-month interval, the researchers divided the patients into three groups: (1) supplemented with beta-glucan and vitamin D, (2) supplemented with vitamin D and placebo, and (3) supplemented with vitamin D alone.

Who Took Part

PubMed indexes the participants as middle-aged adults, older adults and people over 80, both men and women.

How the Study Was Run

In design terms this was a placebo-controlled study.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

What Was Measured

The researchers evaluated the levels of several parameters of inflammatory reactions (C-reactive protein [CRP], serum amyloid A [SAA], and interleukin- [IL-] 6), leptin, and vitamin D.

Topics PubMed links to this paper include Body Mass Index, C-Reactive Protein, Czech Republic, Diabetic Retinopathy, Inflammation, Interleukin-6 and Leptin.

Author keywords: CRP, IL-6, beta-glucan and vitamin D.

What This Means in Plain Language

The paper is a placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in people with diabetic retinopathy and glaucoma.

The publication is from 2019 (Journal of dietary supplements), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Diabetic retinopathy and glaucoma research.